Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa

An update on glucose-6-phosphate dehydrogenase deficiency in children from Brazzaville, Republic of Congo

(2019) Nerly Shirère Gampio Gueye et al.   MALARIA JOURNAL

Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection

(2019) Simon Marie Peko et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study

(2019) Andrea Calcagno et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis

(2019) Pengqiang Du et al.   BIOSCIENCE REPORTS

Distribution of the cytochrome P450 2C8*2 allele in Brazzaville, Republic of Congo

(2019) Simon Marie Peko et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury

(2019) Jingwei Zhang et al.   PLoS One

Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation

(2018) Takahiro Saito et al.   Drug Metabolism and Pharmacokinetics

Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities

(2017) Laure Stella Ghoma Linguissi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women

(2017) Ritah F. Mutagonda et al.   MALARIA JOURNAL

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development

(2017) Iris Rajman et al.   EBioMedicine

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin

(2017) Sandra Soeria-Atmadja et al.   PLoS One

Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients

(2017) Sze Ling Chan et al.   PLoS One

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity

(2016) Zelalem Petros et al.   BMC GENOMICS

Efavirenz pharmacogenetics in a cohort of Italian patients

(2016) Jessica Cusato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)

(2016) Jose R. Castillo-Mancilla et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

(2016) Pamela L. St Jean et al.   MALARIA JOURNAL

tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity

(2016) Julián G. Chamorro et al.   Pharmacogenetics and Genomics

Plasmodium falciparuminfection in febrile Congolese children: prevalence of clinical malaria 10 years after introduction of artemisinin-combination therapies

(2016) Mandingha Kosso Etoka-Beka et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer

(2015) Krishna Kattel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa

(2015) Phumla Z. Sinxadi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis

(2015) Jing Shi et al.   PHARMACOGENOMICS

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

(2015) Milcah Dhoro et al.   BMC Pharmacology & Toxicology

Screening forUGT1A1Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia

(2015) Saran Vardhanabhuti et al.   Open Forum Infectious Diseases

Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study

(2014) T. Nishijima et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The African Genome Variation Project shapes medical genetics in Africa

(2014) Deepti Gurdasani et al.   NATURE

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202

(2014) Daniel H. Johnson et al.   Pharmacogenetics and Genomics

Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance

(2014) Awewura Kwara et al.   PHARMACOTHERAPY

Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity

(2014) Neha Singla et al.   TUBERCULOSIS

Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study

(2013) Cinzia Ciccacci et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria

(2013) Jason W. Bennett et al.   NEW ENGLAND JOURNAL OF MEDICINE

The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity

(2013) Hsin-Tien Ho et al.   Pharmacogenetics and Genomics

Pharmacogenomics, ancestry and clinical decision making for global populations

(2013) E Ramos et al.   PHARMACOGENOMICS JOURNAL

Factors affecting the development of adverse drug reactions (Review article)

(2013) Muaed Jamal Alomar   SAUDI PHARMACEUTICAL JOURNAL

A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir

(2012) Deidre A. Kile et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacogenomics Knowledge for Personalized Medicine

(2012) M Whirl-Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women

(2012) Monica Gandhi et al.   JOURNAL OF INFECTIOUS DISEASES

TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

(2011) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TNF-α genetic polymorphism −308G/A and antituberculosis drug-induced hepatitis

(2011) Sang-Heon Kim et al.   LIVER INTERNATIONAL

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis

(2011) L. Ben Mahmoud et al.   PATHOLOGIE BIOLOGIE

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

(2011) Thorsten Lehr et al.   Pharmacogenetics and Genomics

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

(2011) Kevin C Brown et al.   PHARMACOGENOMICS

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients

(2011) Getnet Yimer et al.   PLoS One

Population Pharmacokinetic Modeling of the Association between 63396C->T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

(2010) A. Schipani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Factors Influencing Severe Atazanavir‐Associated Hyperbilirubinemia in a Population with Low UDP‐Glucuronosyltransferase 1A1*28 Allele Frequency

(2010) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

Toward a more uniform sampling of human genetic diversity: A survey of worldwide populations by high-density genotyping

(2010) Jinchuan Xing et al.   GENOMICS

Global patterns of genetic diversity and signals of natural selection for human ADME genes

(2010) Jing Li et al.   HUMAN MOLECULAR GENETICS

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

(2010) Laure Elens et al.   PHARMACOGENOMICS

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

(2009) William Kudzi et al.   BMC Medical Genetics

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

(2009) Julie Bertrand et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique

(2009) Cinzia Ciccacci et al.   PHARMACOGENOMICS

The Genetic Structure and History of Africans and African Americans

(2009) S. A. Tishkoff et al.   SCIENCE

Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir

(2008) Marco Siccardi et al.   CLINICAL INFECTIOUS DISEASES

High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency

(2008) Caterina I. Fanello et al.   PLoS One